ALVR AlloVir, Inc. Stock Quote

ALVR [NASD]

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	10.70%	Shs Outstand	61.66M	Perf Week	-2.47%
Market Cap	2.71B	Forward P/E	-	EPS next Y	-2.05	Insider Trans	-3.61%	Shs Float	27.46M	Perf Month	3.53%
Income	-69.80M	PEG	-	EPS next Q	-0.42	Inst Own	36.30%	Short Float	7.19%	Perf Quarter	8.26%
Sales	-	P/S	-	EPS this Y	-192.30%	Inst Trans	10.68%	Short Ratio	7.02	Perf Half Y	35.17%
Book/sh	6.06	P/B	6.25	EPS next Y	-16.60%	ROA	-	Target Price	48.00	Perf Year	-
Cash/sh	5.29	P/C	7.16	EPS next 5Y	-	ROE	-	52W Range	18.15 - 48.96	Perf YTD	-1.51%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	51.80%	52W High	-22.67%	Beta	-
Dividend %	-	Quick Ratio	28.40	Sales past 5Y	-	Gross Margin	-	52W Low	108.60%	ATR	3.52
Employees	32	Current Ratio	28.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.76	Volatility	10.55% 8.72%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-949.50%	Profit Margin	-	Rel Volume	0.68	Prev Close	38.38
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	281.49K	Price	37.86
Recom	1.70	SMA20	-8.60%	SMA50	-8.48%	SMA200	9.87%	Volume	191,502	Change	-1.35%

Aug-24-20

Initiated

SVB Leerink

Outperform

$41

Aug-24-20

Initiated

Morgan Stanley

Overweight

$49

Aug-24-20

Initiated

JP Morgan

Overweight

$50

Feb-17-21 07:30AM	AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-11-21 04:00PM	AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Business Wire
07:00AM	AlloVir Reports Full Year 2020 Financial Results Business Wire
Jan-11-21 01:52PM	AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Business Wire +5.89%
Jan-04-21 07:30AM	AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-20 11:21PM	Have Insiders Been Buying AlloVir, Inc. (NASDAQ:ALVR) Shares? Simply Wall St.
Dec-17-20 07:30AM	AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses Business Wire
Dec-11-20 12:54PM	Is ALVR A Good Stock To Buy Now? Insider Monkey
Dec-10-20 01:03PM	Company Profile for AlloVir Business Wire
Dec-07-20 04:30PM	Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting Business Wire -6.52%
Dec-05-20 11:00AM	Preclinical Data Demonstrate Anti-Viral Activity of AlloVirs ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy Business Wire
Nov-24-20 07:30AM	AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-10-20 07:00AM	AlloVir Reports Third Quarter 2020 Financial Results GlobeNewswire -8.94%
Nov-04-20 01:33PM	AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting GlobeNewswire +11.15%
Oct-30-20 06:52AM	Could The AlloVir, Inc. (NASDAQ:ALVR) Ownership Structure Tell Us Something Useful? Simply Wall St.
Oct-21-20 07:30AM	Data to Be Presented at IDWeek 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients GlobeNewswire
Sep-21-20 06:14AM	AlloVir Gains 14% On FDA Trial Nod For Covid-19 Therapy SmarterAnalyst +5.92%
Sep-17-20 09:49AM	AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients GlobeNewswire
Sep-08-20 04:15PM	AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer GlobeNewswire -6.74%
Sep-02-20 07:30AM	AlloVir Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-25-20 07:30AM	AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Aug-03-20 04:30PM	AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-30-20 08:53AM	AlloVir prices upsized IPO at $17, to be valued at over $1 billion MarketWatch
07:32AM	AlloVir Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 23	Sale	39.56	2,118	83,783	494,162	Feb 23 07:44 PM
Vera Juan	Director	Feb 23	Sale	39.40	8,850	348,684	2,403,764	Feb 23 07:44 PM
Leen Ann M.	Chief Scientific Officer	Feb 23	Sale	39.50	4,199	165,876	2,471,685	Feb 23 07:43 PM
Brenner Malcolm	Director	Feb 23	Sale	39.47	8,489	335,036	968,619	Feb 23 07:42 PM
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 22	Sale	42.54	2,800	119,118	496,280	Feb 23 07:44 PM
Vera Juan	Director	Feb 22	Sale	42.57	14,321	609,614	2,412,614	Feb 23 07:44 PM
Leen Ann M.	Chief Scientific Officer	Feb 22	Sale	42.57	5,706	242,880	2,475,884	Feb 23 07:43 PM
Brenner Malcolm	Director	Feb 22	Sale	42.57	11,423	486,246	977,108	Feb 23 07:42 PM
Hagen Brett R	Chief Accounting Officer	Feb 22	Sale	43.14	800	34,509	64,765	Feb 23 07:43 PM
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 19	Sale	41.71	4,165	173,720	499,080	Feb 23 07:44 PM
Vera Juan	Director	Feb 19	Sale	41.79	13,233	553,011	2,426,935	Feb 23 07:44 PM
Leen Ann M.	Chief Scientific Officer	Feb 19	Sale	41.75	7,541	314,868	2,481,590	Feb 23 07:43 PM
Brenner Malcolm	Director	Feb 19	Sale	41.78	11,990	500,935	988,531	Feb 23 07:42 PM
Bornstein Jeffrey S	Director	Feb 18	Sale	40.43	20,583	832,119	0	Feb 23 07:57 PM
Hagen Brett R	Chief Accounting Officer	Feb 18	Sale	40.11	741	29,724	65,565	Feb 19 08:44 AM
Leen Ann M.	Chief Scientific Officer	Feb 18	Sale	40.81	2,700	110,194	2,489,131	Feb 19 08:44 AM
Vera Juan	Director	Feb 18	Sale	40.75	8,942	364,368	2,440,168	Feb 19 08:41 AM
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 18	Sale	40.67	2,085	84,787	503,245	Feb 19 08:41 AM
Brenner Malcolm	Director	Feb 18	Sale	40.75	6,757	275,366	1,000,521	Feb 19 08:38 AM
Vera Juan	Director	Feb 17	Sale	40.34	7,460	300,930	2,449,110	Feb 18 09:25 PM
Brenner Malcolm	Director	Feb 17	Sale	40.45	5,165	208,925	1,007,278	Feb 18 09:24 PM
Leen Ann M.	Chief Scientific Officer	Feb 17	Sale	40.45	2,286	92,468	2,491,831	Feb 18 09:22 PM
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 17	Sale	40.36	2,300	92,837	505,330	Feb 18 09:20 PM
Hagen Brett R	Chief Accounting Officer	Feb 17	Sale	40.42	2,320	93,763	66,306	Feb 18 09:18 PM
Vera Juan	Director	Feb 16	Sale	41.86	10,400	435,365	2,456,570	Feb 18 09:25 PM
Brenner Malcolm	Director	Feb 16	Sale	41.85	6,220	260,332	1,012,443	Feb 18 09:24 PM
Leen Ann M.	Chief Scientific Officer	Feb 16	Sale	41.88	3,050	127,733	2,494,117	Feb 18 09:22 PM
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 16	Sale	41.86	3,100	129,770	507,630	Feb 18 09:20 PM
Hagen Brett R	Chief Accounting Officer	Feb 16	Sale	41.91	3,050	127,816	68,626	Feb 18 09:18 PM
Melian Agustin	Chief Medical Officer	Feb 02	Sale	41.19	54,849	2,259,230	520,266	Feb 04 04:35 PM
VAN BEEK JEROEN B	Chief Commercial Officer	Feb 02	Sale	41.19	48,910	2,014,603	510,730	Feb 04 04:35 PM
Jovan-Embiricos Morana	Director	Aug 03	Buy	17.00	2,900,000	49,300,000	2,800,000	Aug 06 06:06 AM
VAN BEEK JEROEN B	Chief Commercial Officer	Aug 03	Buy	17.00	3,000	51,000	524,640	Aug 05 09:55 PM
Brainard Diana	Director	Aug 03	Buy	17.00	6,300	107,100	6,300	Aug 05 09:42 PM
Atillasoy Ercem	See Remarks	Aug 03	Buy	17.00	3,500	59,500	78,500	Aug 05 09:39 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience